Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
NCT06081283 · University of North Carolina, Chapel Hill · PHASE4 · terminated · last registry update 2025-11-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment” | – | Registry record, University of North Carolina, Chapel Hill |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SV2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-21Results posted on the registry: University of Colorado, Denver, Levetiracetam + Placebo (NCT02647437)
- 2026-06-03Also stopped (terminated): University of Rochester, Brivaracetam (NCT05029960)
- 2026-05-04Phase 3 first posted: Jiangxi Qingfeng Pharmaceutical Co. Ltd., Brivaracetam (NCT07563634)
- 2026-03-24Phase 3 first posted: Waad Alkathiri, Levetiracetam (NCT07490769)
- 2026-03-18Results posted on the registry: University of Minnesota, brivaracetam + Placebo (NCT05639946)
- 2026-01-13Phase 3 first posted: Hospices Civils de Lyon, Treatment administration (Levetiracetam or placebo) (NCT07336992)
- 2025-11-20Phase 3 first posted: Beijing Tiantan Hospital, Levetiracetam + Placebo (NCT07239115)
- 2025-11-18Phase 3 first posted: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Levetiracetam 500mg + Placebo (NCT07234695)
- 2025-10-24Phase 3 first posted: Nebraska Methodist Health System, Levetiracetam + magnesium sulfate (NCT07220902)
- 2025-10-07Results posted on the registry: UCB Biopharma SRL, Brivaracetam Film-coated tablet + Brivaracetam oral solution (NCT05109234)
- 2025-07-29Results posted on the registry: UCB Biopharma SRL, Brivaracetam (NCT03250377)
- 2025-07-14Results posted on the registry: VA Office of Research and Development, Levetiracetam + Placebo (NCT03034356)
- 2025-07-08Results posted on the registry: Mario Negri Institute for Pharmacological Research, Low dose carbamazepine + Standard dose carbamazepine (NCT03689114)
- 2025-07-03Results posted on the registry: Janssen Research & Development, LLC, JNJ-40411813 + Placebo (NCT04836559)
- 2025-07-01Phase 3 first posted: Sohag University, Ketamine + Levetiracetam (NCT07046611)
- 2025-06-06Results posted on the registry: UCB Biopharma SRL, brivaracetam (BRV) tablet + brivaracetam (BRV) dry syrup (NCT06312566)
- 2025-05-25Also stopped (withdrawn): AgeneBio, AGB101 + Placebo (NCT05986721)
- 2025-04-27Results posted on the registry: University of Minnesota, Brivaracetam (NCT04379011)
- 2025-04-02Phase 3 first posted: University of Virginia, Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) + Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET) (NCT06907173)
- 2025-02-28Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Levetiracetam IV (NCT06851078)
- 2025-01-14Phase 3 first posted: Shanghai East Hospital, Levetiracetam (NCT06773364)
- 2024-12-27Phase 3 first posted: Tanta University, Dapagliflozin placebo + Placebo (NCT06750458)
- 2024-11-29Results posted on the registry: University of Michigan, Levetiracetam (NCT01801072)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision